Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Scientific Officer

Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

Chief Medical Officer

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeu...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-12-05	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-12-05	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-12-05	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-12-05	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2023-10-12	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2023-08-23	Premium	sold	Premium	Premium	Premium	-
2023-03-28	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2022-06-09	Premium	sold	Premium	Premium	Premium	-
2022-06-09	Premium	acquired	Premium	Premium	Premium	-
2022-06-08	Premium	acquired	Premium	Premium	Premium	-
2022-06-08	Premium	sold	Premium	Premium	Premium	-
2022-05-11	Premium	sold	Premium	Premium	Premium	-
2022-05-10	Premium	sold	Premium	Premium	Premium	-
2022-05-09	Premium	sold	Premium	Premium	Premium	-
2022-05-02	Premium	sold	Premium	Premium	Premium	-
2022-04-29	Premium	sold	Premium	Premium	Premium	-
2022-04-28	Premium	sold	Premium	Premium	Premium	-
2022-04-18	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-04-18	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2022-03-23	Premium	bought	Premium	Premium	Premium	-
2022-03-22	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2022-03-22	Premium	bought	Premium	Premium	Premium	-
2022-03-17	Premium	sold	Premium	Premium	Premium	-
2022-03-11	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2022-03-11	Premium	sold	Premium	Premium	Premium	Chief Medical Officer

ITOS - iTeos Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for ITOS